Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-089326
Filing Date
2024-08-01
Accepted
2024-08-01 16:24:46
Documents
97
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q bbio-20240630.htm   iXBRL 10-Q 3738849
2 EX-10.1 bbio-ex10_1.htm EX-10.1 2053999
3 EX-10.2 bbio-ex10_2.htm EX-10.2 810026
4 EX-31.1 bbio-ex31_1.htm EX-31.1 24790
5 EX-31.2 bbio-ex31_2.htm EX-31.2 24910
6 EX-32.1 bbio-ex32_1.htm EX-32.1 11409
7 EX-32.2 bbio-ex32_2.htm EX-32.2 11673
  Complete submission text file 0000950170-24-089326.txt   20398477

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT bbio-20240630.xsd EX-101.SCH 2710698
100 EXTRACTED XBRL INSTANCE DOCUMENT bbio-20240630_htm.xml XML 3248397
Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38959 | Film No.: 241167124
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)